drugset / Trial / NCT07063225
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Phase 2
Recruiting
50 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Henan Cancer Hospital · collabThe Second Affiliated Hospital of Kunming Medical University · collabTianjin Medical University Cancer Institute and Hospital · collabTianjin Medical University Second Hospital · collabTianjin People's Hospital · collabTianjin Third Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
Timeline
- Start
- 2025-08
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romiplostim N01 | Peptide | 10 ug/kg | Subcutaneous |